Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial
Author:
Funder
AstraZeneca
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference19 articles.
1. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Canc Discov,2014
2. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer;Janne;N Engl J Med,2015
3. Osimertinib or platinum-pemetrexed in EGFR t790m-positive lung cancer;Mok;N Engl J Med,2017
4. Mechanisms of osimertinib resistance and emerging treatment options;Schmid;Lung Canc,2020
5. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review;Piper-Vallillo;J Clin Oncol,2020
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Construction of a bioinformatics-based prognostic model related to liquid-liquid phase separation in lung adenocarcinoma;2024-01-10
2. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study;Annals of Oncology;2024-01
3. Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies;Exploration of Targeted Anti-tumor Therapy;2023-10-10
4. A Meta-analysis of Randomised Controlled Trials Comparing Combination Therapy as Second-line Treatment With Monotherapy in Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation;American Journal of Clinical Oncology;2023-10-02
5. Neoadjuvant therapy in non-small cell lung cancer;Critical Reviews in Oncology/Hematology;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3